Cencora, Inc. (COR)

Over the past six months, Cencora's stock price increased by 30.23% between February 5, 2025, and February 4, 2026, and by 36.94% between January 29, 2025, and January 28, 2026. Cencora's stock has delivered a 44.52% change over the past year, with a 52-week range between $237.71 and $377.54. In November 2024, Cencora agreed to acquire Retina Consultants of America for approximately $4.6 billion in cash, with up to $500 million in contingent consideration. In November 2025, Cencora announced a $1 billion investment through 2030 to strengthen its U.S. distribution network. On February 4, 2026, Cencora reported its fiscal first-quarter results, with revenue increasing by 5.5% year-over-year to $85.9 billion and adjusted diluted EPS rising by 9.4% to $4.08, surpassing analyst consensus. The company raised its adjusted operating income guidance for fiscal year 2026 to a growth of 11.5% to 13.5%. Despite beating EPS expectations and raising its full-year operating outlook, Cencora's stock fell by 8.8% on February 5, 2026, due to the marginal revenue miss and a decline in international operating income.

While specific demand seasonality is not detailed, Cencora focuses on supply chain demand planning, assisting clients in utilizing operational data to reduce overproduction risk and improve alignment with commercial and regulatory timelines. The company provides insights from real-time reporting, inventory analysis, and forecast modeling, suggesting that managing demand fluctuations is a core aspect of its services. Strong demand for GLP-1 (weight loss) and oncology therapies has been noted as a driver for the U.S. Healthcare Solutions segment's performance.

Cencora, Inc., formerly AmerisourceBergen Corporation, is a global pharmaceutical solutions organization founded in 1871 and headquartered in Conshohocken, Pennsylvania. It operates in the healthcare sector, providing end-to-end pharmaceutical distribution, commercialization support, and related services to manufacturers, healthcare providers, pharmacies, hospitals, and health systems worldwide. Cencora distributes brand-name, specialty brand-name, generic, and injectable pharmaceuticals, along with over-the-counter healthcare products, and home healthcare supplies and equipment. The company operates through U.S. Healthcare Solutions and International Healthcare Solutions segments, offering various services, including wholesale and specialty distribution, pharmacy solutions, and drug research support. Cencora also provides global specialty drug logistics through World Courier and animal health product distribution via MWI Animal Health.

Cencora has a significant global presence, operating in over 50 countries, including the United States, Canada, and other international markets. The acquisition of Alliance Healthcare in 2021 bolstered its international expansion in Europe. Cencora has 26 pharmaceutical distribution centers in the U.S., nine in Canada, and four specialty distribution centers in the U.S., along with over 1 million square feet of packaging production capacity in the U.S. and the U.K. World Courier adds over 150 company-owned offices globally to Cencora's network.

Cencora's brand reputation is characterized by its market dominance in the U.S. pharmaceutical wholesale industry, holding over 90% market share alongside McKesson and Cardinal Health. The acquisition of Alliance Healthcare has solidified its position in the European market. The rebranding from AmerisourceBergen Corporation to Cencora, Inc. in August 2023 signifies a global unification for customer and patient care. The company's strategic pivot towards high-margin specialty healthcare platforms, including the acquisition of OneOncology and Retina Consultants of America, has been highlighted as a positive development.

Cencora, Inc. has a significant institutional ownership base, with 2203 to 2264 institutional owners and shareholders holding a total of 214,938,260 to 215,868,359 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Price T Rowe Associates Inc /md/, and Geode Capital Management, Llc. Walgreens Boots Alliance, Inc. also holds a notable stake. As of January 5, 2026, Vanguard Group held 23,310,032 shares (12.02%), BlackRock Institutional Trust Company held 12,812,991 shares (6.60%), and State Street Investment Management held 9,190,316 shares (4.74%). Walgreens Boots Alliance held 7,473,000 shares (3.85%).